{
    "organizations": [],
    "uuid": "e12e34f8f0c1c6aef99ad9b8183d5bef97be4c25",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-innate-pharma-announces-promising/brief-innate-pharma-announces-promising-anti-tumor-activity-of-monalizumab-with-cetuximab-in-scchn-idUSFWN1RU19F",
    "ord_in_thread": 0,
    "title": "BRIEF-Innate Pharma Announces Promising Anti-Tumor Activity Of Monalizumab With Cetuximab In SCCHN",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 17 (Reuters) - INNATE PHARMA SA:\n* PROMISING ANTI-TUMOR ACTIVITY OF MONALIZUMAB WITH CETUXIMAB IN SCCHN\n* 8 PARTIAL RESPONSES IN 26 PATIENTS EVALUABLE FOR EFFICACY IN MONALIZUMAB PHASE I/II TRIAL\n* NUMBER OF RESPONSES NEEDED TO DECLARE TRIAL RESULT POSITIVE IS REACHED\n* COMBINATION WAS WELL TOLERATED, WITHOUT POTENTIATING CETUXIMAB-RELATED SIDE EFFECTS\n* TOTAL ENROLLMENT OF 40 PATIENTS NOW COMPLETED Source text: bit.ly/2J3tCYk Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-04-18T03:05:00.000+03:00",
    "crawled": "2018-04-18T18:19:55.031+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "innate",
        "pharma",
        "sa",
        "promising",
        "activity",
        "monalizumab",
        "cetuximab",
        "scchn",
        "partial",
        "response",
        "patient",
        "evaluable",
        "efficacy",
        "monalizumab",
        "phase",
        "trial",
        "number",
        "response",
        "needed",
        "declare",
        "trial",
        "result",
        "positive",
        "reached",
        "combination",
        "well",
        "tolerated",
        "without",
        "potentiating",
        "side",
        "effect",
        "total",
        "enrollment",
        "patient",
        "completed",
        "source",
        "text",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}